More than 60 million people globally are affected by glaucoma that can lead to progressive damage of the optic nerve. The CyPass Micro-Stent is a prescription medical device that is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle glaucoma.
Alcon, the global leader in eye care and a division of Novartis, announced the US launch of the CyPass® Micro-Stent at the annual meeting of the American Academy of Ophthalmology (AAO), October 15-18 in Chicago, where Alcon will host a live training program and present additional data during poster and oral sessions. The CyPass Micro-Stent was approved by the US Food and Drug Administration in July for use in conjunction with cataract surgery to lower intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma.
“We are excited to launch the CyPass Micro-Stent device in a new segment of glaucoma treatment called minimally-invasive glaucoma surgery, or MIGS,” says Sergio Duplan, Region President, North America, Alcon. “This new treatment option for cataract patients with mild to moderate primary open-angle glaucoma has been demonstrated to have a lasting, significant IOP-lowering effect.”
The CyPass Micro-Stent device is implanted during cataract surgery, just below the surface of the eye, into the supraciliary space. It is designed to lower IOP by enhancing aqueous outflow through one of the natural drainage pathways of the eye, with minimal tissue disruption, which allows the excess fluid in the eye to drain. The CyPass Micro-Stent was developed by Transcend Medical, Inc. which Alcon acquired in February 2016.
As part of its activities at AAO, Alcon will present two- and three-year data from COMPASS, the largest study of MIGS to date, as well as three-year data findings from the CYCLE study (a real-world registry study conducted in the EU).
Two-year data from the landmark COMPASS study was also published recently in the online edition of the peer-reviewed journal Ophthalmology. The data published in Ophthalmology is a follow-up for over 500 mild to moderate glaucoma patients who underwent cataract surgery. The randomized clinical study demonstrated safe and sustained two-year reduction in intraocular pressure and glaucoma medication use after micro-interventional surgical treatment for mild-to-moderate primary open-angle glaucoma.
“Findings from the COMPASS and CYCLE studies are significant and further demonstrate Alcon’s dedication to bringing to market some of the most innovative surgical technologies to effectively treat diseases like glaucoma,” said Franck Leveiller, Head of Global Research & Development, Alcon. “We are proud to be working with glaucoma experts and surgeons in the US and around the world to bring this new treatment option to as many eligible patients as possible.”